Celldex Therapeutics
CLDX
141 hedge funds and large institutions have $348M invested in Celldex Therapeutics in 2016 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 46 increasing their positions, 51 reducing their positions, and 20 closing their positions.
9% more capital invested
Capital invested by funds: $319M → $348M (+$29.2M)
3% more call options, than puts
Call options by funds: $3.23M | Put options by funds: $3.12M
10% less repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 51
3% less funds holding
Funds holding: 145 → 141 (-4)
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
+$9.67M |
| 2 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$8.14M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$7M |
| 4 |
PP
PDT Partners
New York
|
+$2.1M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$2.08M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$15.2M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$11.7M |
| 3 |
First Trust Advisors
Wheaton,
Illinois
|
-$10.3M |
| 4 |
Millennium Management
New York
|
-$9.87M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.34M |
CLDX Hedge Fund Activity: Q2 2016 in Review
141 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2016, worth a combined $348M — up 9.2% from $319M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CLDX and 18 opened new positions — a net loss of 2 holders — while 51 trimmed existing stakes and 46 added.
The largest buyer was Columbia Wanger Asset Management, adding an estimated $9.67M. The largest seller was State Street, cutting an estimated $15.2M.
- 141 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2016, down from 145 in Q1 2016.
- Funds reported $348M of Celldex Therapeutics stock for Q2 2016, up 9.2% quarter-over-quarter.
- 18 funds opened new Celldex Therapeutics positions in Q2 2016 and 20 closed out, a net change of -2 holders.
- The largest Celldex Therapeutics buyer in Q2 2016 was Columbia Wanger Asset Management, an estimated $9.67M added.
- The largest Celldex Therapeutics seller in Q2 2016 was State Street, an estimated $15.2M sold.
Based on aggregated 13F filings for Q2 2016.